Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation.
To develop a new therapeutic monoclonal Antibody (mAb) for Hodgkin lymphoma (HL), we immunized a BALB/c mouse with live HL cell lines, alternating between two HL cell lines. After hybridization, we screened the hybridoma clones by assessing direct cytotoxicity against a HL cell line not used for imm...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4814124?pdf=render |
| _version_ | 1818499140004347904 |
|---|---|
| author | Shuji Matsuoka Yasuyuki Ishii Atsuhito Nakao Masaaki Abe Naomi Ohtsuji Shuji Momose Hui Jin Hisashi Arase Koichi Sugimoto Yusuke Nakauchi Hiroshi Masutani Michiyuki Maeda Hideo Yagita Norio Komatsu Okio Hino |
| author_facet | Shuji Matsuoka Yasuyuki Ishii Atsuhito Nakao Masaaki Abe Naomi Ohtsuji Shuji Momose Hui Jin Hisashi Arase Koichi Sugimoto Yusuke Nakauchi Hiroshi Masutani Michiyuki Maeda Hideo Yagita Norio Komatsu Okio Hino |
| author_sort | Shuji Matsuoka |
| collection | DOAJ |
| description | To develop a new therapeutic monoclonal Antibody (mAb) for Hodgkin lymphoma (HL), we immunized a BALB/c mouse with live HL cell lines, alternating between two HL cell lines. After hybridization, we screened the hybridoma clones by assessing direct cytotoxicity against a HL cell line not used for immunization. We developed this strategy for establishing mAb to reduce the risk of obtaining clonotypic mAb specific for single HL cell line. A newly established mouse anti-human mAb (4713) triggered cytoskeleton-dependent, but complement- and caspase-independent, cell death in HL cell lines, Burkitt lymphoma cell lines, and advanced adult T-cell leukemia cell lines. Intravenous injection of mAb 4713 in tumor-bearing SCID mice improved survival significantly. mAb 4713 was revealed to be a mouse anti-human pan-HLA class II mAb. Treatment with this mAb induced the formation of large pores on the surface of target lymphoma cells within 30 min. This finding suggests that the cell death process induced by this anti-pan HLA-class II mAb may involve the same death signals stimulated by a cytolytic anti-pan MHC class I mAb that also induces large pore formation. This multifaceted study supports the therapeutic potential of mAb 4713 for various forms of lymphoma. |
| first_indexed | 2024-12-10T20:25:14Z |
| format | Article |
| id | doaj.art-d364300c7b7948fdb551b743738da2ba |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T20:25:14Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-d364300c7b7948fdb551b743738da2ba2022-12-22T01:34:54ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01113e015049610.1371/journal.pone.0150496Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation.Shuji MatsuokaYasuyuki IshiiAtsuhito NakaoMasaaki AbeNaomi OhtsujiShuji MomoseHui JinHisashi AraseKoichi SugimotoYusuke NakauchiHiroshi MasutaniMichiyuki MaedaHideo YagitaNorio KomatsuOkio HinoTo develop a new therapeutic monoclonal Antibody (mAb) for Hodgkin lymphoma (HL), we immunized a BALB/c mouse with live HL cell lines, alternating between two HL cell lines. After hybridization, we screened the hybridoma clones by assessing direct cytotoxicity against a HL cell line not used for immunization. We developed this strategy for establishing mAb to reduce the risk of obtaining clonotypic mAb specific for single HL cell line. A newly established mouse anti-human mAb (4713) triggered cytoskeleton-dependent, but complement- and caspase-independent, cell death in HL cell lines, Burkitt lymphoma cell lines, and advanced adult T-cell leukemia cell lines. Intravenous injection of mAb 4713 in tumor-bearing SCID mice improved survival significantly. mAb 4713 was revealed to be a mouse anti-human pan-HLA class II mAb. Treatment with this mAb induced the formation of large pores on the surface of target lymphoma cells within 30 min. This finding suggests that the cell death process induced by this anti-pan HLA-class II mAb may involve the same death signals stimulated by a cytolytic anti-pan MHC class I mAb that also induces large pore formation. This multifaceted study supports the therapeutic potential of mAb 4713 for various forms of lymphoma.http://europepmc.org/articles/PMC4814124?pdf=render |
| spellingShingle | Shuji Matsuoka Yasuyuki Ishii Atsuhito Nakao Masaaki Abe Naomi Ohtsuji Shuji Momose Hui Jin Hisashi Arase Koichi Sugimoto Yusuke Nakauchi Hiroshi Masutani Michiyuki Maeda Hideo Yagita Norio Komatsu Okio Hino Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation. PLoS ONE |
| title | Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation. |
| title_full | Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation. |
| title_fullStr | Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation. |
| title_full_unstemmed | Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation. |
| title_short | Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation. |
| title_sort | establishment of a therapeutic anti pan hla class ii monoclonal antibody that directly induces lymphoma cell death via large pore formation |
| url | http://europepmc.org/articles/PMC4814124?pdf=render |
| work_keys_str_mv | AT shujimatsuoka establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT yasuyukiishii establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT atsuhitonakao establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT masaakiabe establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT naomiohtsuji establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT shujimomose establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT huijin establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT hisashiarase establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT koichisugimoto establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT yusukenakauchi establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT hiroshimasutani establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT michiyukimaeda establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT hideoyagita establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT noriokomatsu establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation AT okiohino establishmentofatherapeuticantipanhlaclassiimonoclonalantibodythatdirectlyinduceslymphomacelldeathvialargeporeformation |